Turn-off and turn-on with hard switching at <i>f</i>_<i>r</i><i>/2</i> < <i>f</i>_<i>SL</i>(50 kHz) < <i>f</i>_<i>r</i> of the switch <i>S</i><sub><i>... by M. Zakir Hossain (6033752)

Protein levels of Bcl-2 family markers in limbal stromal cells (LSCs) and in Aniridia-LSCs (AN-LSCs), after treatment with 0 µM, 50 µM and 75 µM Cobalt chloride (CoCl₂),... by Shanhe Liu (5251313)

Crystal structures of Triosephosphate Isomerases from <i>Taenia solium</i> and <i>Schistosoma mansoni</i> provide insights for vaccine rationale and drug design against helminth pa... by Pedro Jimenez-Sandoval (831603)

“…This insert is located between α5 and β6 and is proposed to be the main TPI epitope. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”

ROS levels. by Bo Huang (30906)

“…At 8 h following 2Gy radiation, the ROS level decreased approximately 10% compared to 2 h. Although Sema3a also decreased the ROS level, the differences between the 0ng/ml of Sema3a group and the 50ng/ml Sema3a group were not statistically significant (P>0.05, N = 5).…”

Synthesis of Triazole-Substituted Quinazoline Hybrids for Anticancer Activity and a Lead Compound as the EGFR Blocker and ROS Inducer Agent by Biswadip Banerji (482320)

“…A series of triazole-substituted quinazoline hybrid compounds were designed and synthesized for anticancer activity targeting epidermal growth factor receptor (EGFR) tyrosine kinase. …”